Emerging treatments

Novel antiviral agents

The development of new anti-orthopoxvirus treatments remains an active area of research. NIOCH-14, an analog of tecovirimat, is an investigational oral antiviral agent with in vitro and in vivo activity against orthopoxviruses.[38] Phase 1 trials in Russia have shown that oral regimens were safe. Several nucleoside analog inhibitors have shown in vitro activity against poxviruses, including: N-methanocarbathymidine, the 4′-thio derivative of idoxuridine, and KAY-2-41.[39]

Fourth-generation vaccinia vaccines

In the future, it is expected that subunit vaccines will be developed and deployed.[40] A fourth-generation attenuated vaccinia vaccine (VACΔ6) has been developed in Russia.[41]

Use of this content is subject to our disclaimer